{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014405","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.111177+00:00","generated_at":"2026-05-22T19:48:11.155379+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxart updates: BARDA stop-work lifted, norovirus enrollment done, reverse split proposal","bullets":["BARDA stop-work order on COVID-19 Phase 2b trial lifted April 24, 2025; 10,000-participant portion pending BARDA approval.","Norovirus program: all 60 participants enrolled in under 2 months; topline data expected mid-2025.","Cost reductions including workforce cuts extended cash runway into 2026; seeking additional non-dilutive funding.","Annual meeting May 21, 2025; board seeks reverse stock split approval to avoid Nasdaq delisting; ISS and Glass Lewis recommend FOR.","Q1 2025 earnings call scheduled for May 13, 2025; webcast at Citizens Life Sciences Conference on May 7."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014405","json":"https://secwatch.observer/filing/0001437749-25-014405.json","markdown":"https://secwatch.observer/filing/0001437749-25-014405.md","text":"https://secwatch.observer/filing/0001437749-25-014405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/0001437749-25-014405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925014405/vxrt20250503_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T19:48:11.155379+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}